Product
CH505 TF chTrimer+ALFQ
1 clinical trial
1 indication
Indication
HIVClinical trial
Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy AdultsStatus: Not yet recruiting, Estimated PCD: 2024-12-01